Clinical Trial Update: Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Xyrem for excessive daytime sleepiness and sleep disturbance in Parkinson's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Xyrem (Sodium Oxybate)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Parkinson Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-09-28